Since PPTases catalyze the transfer of the 4'-phosphopantetheine moiety from coenzyme A (CoA) to the conserved serine residue on carrier proteins like BpsA, we know the modification converts the inactive apo-form of the carrier protein into its active holo-form, enabling it to participate in biosynthetic pathways.
We recognize two types each with distinct roles in cellular metabolism. AcpS-type PPTases mostly modify acyl carrier proteins (ACPs) involved in primary metabolism, such as fatty acid synthesis. On the other hand, Sfp-type PPTases have a broader substrate specificity and can modify both ACPs and peptidyl carrier proteins involved in secondary metabolism, such as polyketide and non-ribosomal peptide synthesis. These interesting enzymes enable our drug discovery process. The process of 4'-phosphopantetheinylation involves several key steps. Initially, the PPTase binds to CoA, positioning the 4'-phosphopantetheine group for transfer. Next, the PPTase recognizes and binds to the apo-form of the carrier protein, specifically targeting the conserved serine residue. The PPTase then catalyzes the transfer of the 4'-phosphopantetheine group from CoA to the serine residue on the carrier protein. Naturally this very reaction involves the formation of a covalent bond between the serine hydroxyl group and the phosphopantetheine moiety. Ultimate, the modified carrier protein, now in its active holo-form, is released from the PPTase and can participate in the biosynthetic pathway.
Regarding structural analysis, since the active site of PPTases is designed to facilitate the precise positioning of CoA and the carrier protein, and key amino acid residues within the active site interact with the phosphopantetheine group and the serine residue, ensuring efficient catalysis, structural studies (for example through X-ray crystallography or cryo-EM), will provide detailed insights into the configuration of these active sites.
Previous directed evolution experiments have identified several key residues in BpsA that enhance its interaction with non-cognate PPTases. Those mutations often occur near the active site, altering the surface properties of BpsA to improve binding affinity and catalytic efficiency. For example, mutations that increase the hydrophobicity or alter the charge distribution around the serine residue can enhance the recognition and binding of PPTases. We can draw from these experiments to optimize our drugdiscovery process. In order to understand the potential of BpsA Variants, let us investigate their biochemical qualities. Evolved BpsA variants have certain qualities and studying their biochemical characterization will aid our development process. Since the Michaelis constant and the maximum reaction rate parameters provide insights into the efficiency and specificity of the evolved enzymes, we can note how variants with lower Km values and higher Vmax values are considered more efficient, as they have a higher affinity for the substrate and a faster catalytic rate. Understanding the stability and solubility of evolved BpsA variants is of essence. While we could indeed introduce mutations that enhance the thermal stability, pH tolerance, and solubility of BpsA, we need to make sure the endresult has robust qualities, especially under various conditions, hence we assess these properties through thermal denaturation assays, solubility tests, and additional long-term stability studies.
Colorimetric and fluorescence-based (functional) assays, are employed to assess the activation of BpsA by PPTases. We measure the production of indigoidine, the blue pigment synthesized by BpsA, as an indicator of enzyme activity. Note how variants that produce higher levels of indigoidine are considered more optimal activated by PPTases. In vivo assays in microbial hosts, ( Escherichia coli or yeast ), help us evaluate the production of the desired compounds. Here we take into account expression levels, metabolic flux and cellular environment to name a few.
Since a deep understanding of the molecular chemistry involved in the disorder's pathophysiology is required, ASD being a broad spectrum, we recognize the complexity of the spectrum, consistent of genetic, environmental, and neurobiological factors, leading to a wide range of symptoms and severities. Addressing the underlying causes (instead of merely managing symptoms) is realistic for several reasons. Modulation of neurotransmitter systems such as serotonin, dopamine, and gamma-aminobutyric acid (GABA) play crucial roles in regulating mood, behavior, and cognition. We know from previous research ,imbalances in these neurotransmitter systems have been implicated in ASD. Compounds that can modulate these systems are of interest since they hold potential as therapeutic agents. Serotonin Modulators are one such class of compounds. Selective serotonin reuptake inhibitors (SSRIs) are commonly used to manage anxiety and depression in ASD. Their efficacy is limited, and they often come with side effects. Novel compounds that can more precisely target serotonin receptors or modulate serotonin synthesis and degradation pathways should be investigated since they could offer improved therapeutic outcomes. Dopamine Modulators function differently, and while dopamine dysregulation is associated with repetitive behaviors and reward processing deficits in ASD, the Dopamine receptor agonists and antagonists, as well as compounds that influence dopamine synthesis and release, are potential candidates for ASD treatment. More research is underway regarding the effect of Dopamine. GABAergic Compounds also hold promise. The primary inhibitory neurotransmitter in the brain, its dysregulation is linked to the excitatory-inhibitory imbalance. Enhancing GABAergic signalling through GABA receptor agonists or inhibitors of GABA reuptake and degradation could help restore this balance.
Optimizing Drug-Like Properties
One of the hallmarks of ASD is Synaptic dysfunction. With alterations in synaptic connectivity and plasticity contributing to the disorder's symptoms, synaptic connectivity remains a point of interest. Compounds that can enhance synaptic function and promote synaptic plasticity are of great interest. Neurotrophic Factors, such as brain-derived neurotrophic factor (BDNF) and other neurotrophic factors, play critical roles in synaptic plasticity and neuronal survival. We could enhance the expression (or activity) of these neurotrophic factors and hence, improve synaptic function in ASD. mGluR Modulators are also being explored. Metabotropic glutamate receptors (mGluRs) are involved in (synaptic) plasticity and have been implicated in ASD. mGluR5 antagonists, for example, have shown promise in preclinical models of ASD by reducing excessive synaptic signalling and improving behavioral outcomes.
Regarding existing therapeutics and their functional groups and structural motifs , we can use computational modelling to attain detailed insights into the molecular structures of existing and hence plausible new drugs. We generally use this information to identify key binding sites and interactions with target proteins. Investigating the mechanisms of action of existing drugs can reveal the pathways and processes they influence. We can improve the design of new compounds that target the same pathways more optimal or with fewer side effects. Designing new novel compounds with improved properties takes time.First, Identifying Core Structures is essential. Next, Introducing Modifications involves making chemical changes to these core structures to enhance their activity, selectivity, and pharmacokinetic properties. These modifications can include the addition of functional groups, changes in stereochemistry, and the incorporation of bioisosteres. Finally, Optimizing Drug-Like Properties ensures that the new compounds are suitable for therapeutic use by improving their solubility, stability, and bioavailability.
Positive allosteric modulators of AMPA receptors or inhibitors of synaptic protein degradation (in the case of synaptic modulators) could improve cognitive and behavioral outcomes. Neuroprotective Agents that prevent synaptic damage and promote neuronal survival, such as antioxidants and anti-inflammatory compounds, could mitigate the neurodevelopmental deficits.
Selective Receptor Agonists/Antagonists are designed to target specific neurotransmitter receptors, such as serotonin 5-HT1A or dopamine D2 receptors, and they provide more targeted and effective treatments for ASD symptoms, hence modulating neurotransmitter systems seems realistic. Enzyme Inhibitors that inhibit enzymes involved in neurotransmitter synthesis and degradation, such as monoamine oxidase inhibitors (MAOIs) or GABA transaminase inhibitors, could in theory, help restore neurotransmitter balance. Derivatives, of natural libraries, can be of use, if we invest into chemically modifying these natural products to enhance their activity and drug-like properties, yielding novel compounds with improved efficacy and safety profiles. Since initially, the PPTase binding to CoA, positions the 4'-phosphopantetheine group for transfer, (this binding facilitated by specific interactions between the PPTase and the CoA molecule which are critical for the subsequent transfer reaction) natural products could be once more investigated.
When the PPTase recognizes and binds to the apo-form of the BpsA carrier protein, ( targeting the conserved serine residue) a series of molecular interactions are at play, mediating the process, and they ensure the precise alignment of the carrier protein and the PPTase. Expanding existing libraries will improve our drug development process and in theory, the alignment process involved, could be studied again in order to assess potential. Furthermore the active site of the PPTase (while the catalytic transfer is taking place) ,providing the necessary catalytic environment for the bond formation can be studied further. When the transfer is complete, the modified carrier protein, as we have mentioned before, (in its active holo-form,) is released from the PPTase and can participate in the biosynthetic pathway.
© All rights reserved. Do not distribute. (Article: Directed Evolution of the BpsA Carrier Protein Domain for Enhanced Activation by Non-Cognate 4'-Phosphopantetheinyl Transferases Implications for ASD Drug Discovery)